An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
NCT03740230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3134
Last updated 2024-07-19
Summary
Post-marketing surveillance study to evaluate the real world safety and effectiveness of Maviret (Glecaprevir/Pibrentasvir) administered under a normal, routine treatment practice by Korean patients with Chronic Hepatitis C Genotypes 1 to 6
Conditions
- Hepatitis C
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-09-26
- Primary Completion
- 2023-07-21
- Completion
- 2023-07-21
Countries
- South Korea
Study Locations
More Related Trials
-
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
NCT03222583 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis
NCT03089944 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs
NCT03201718 ·Status: COMPLETED
-
A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
NCT04214028 ·Status: COMPLETED
-
Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
NCT02727933 ·Status: COMPLETED
-
Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation
NCT03868163 ·Status: COMPLETED
-
Glecaprevir/Pibrentasvir Real-world Study in China
NCT03941821 ·Status: UNKNOWN
-
Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6
NCT03303599 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
NCT03069365 ·Status: COMPLETED ·Phase: PHASE3
-
36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8
NCT01683786 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection
NCT02021643 ·Status: COMPLETED ·Phase: PHASE3
-
Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients
NCT03117569 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response
NCT04577482 ·Status: COMPLETED
-
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
NCT02939989 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation
NCT04189627 ·Status: COMPLETED
-
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection
NCT02021656 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis
NCT04352309 ·Status: COMPLETED
-
Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
NCT02074514 ·Status: COMPLETED ·Phase: PHASE3
-
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)
NCT02615145 ·Status: COMPLETED
-
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
NCT03067129 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C
NCT00629824 ·Status: COMPLETED ·Phase: PHASE4
-
The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France
NCT02618928 ·Status: COMPLETED
-
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
NCT01371578 ·Status: COMPLETED ·Phase: PHASE2
-
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
NCT01682720 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
NCT02581163 ·Status: COMPLETED